Gilead Sciences Announces New Results From a Post Hoc Analysis of Livdelzi in Primary Biliary Cholangitis
Gilead Sciences (NASDAQ: GILD) announced new results from a post hoc analysis showing that its drug, Livdelzi, achieved high and sustained normalization rates for a key liver marker among patients with primary biliary cholangitis. The findings highlight the potential of Livdelzi in treating PBC patients who remain elevated in ALP levels despite prior therapy.
Topics: Gilead Sciences Livdelzi Phase 3 study primary biliary cholangitis (PBC)